CLINICAL USE


Induction and maintenance of remission in ulcerative colitis

DOSE IN NORMAL RENAL FUNCTION

Dose depends on preparation

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :153.1
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :40–50
  • %Excreted unchanged in urine &nbsp &nbsp : No data

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :No data

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :0.6/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Caution – use only if necessary. Start with low dose and increase according to response
  • 10 to 20 &nbsp &nbsp : Caution – use only if necessary. Start with low dose and monitor closely
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Caution – use only if necessary. Start with low dose and monitor closely

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral, PR

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Mesalazine is excreted rapidly by the kidney, mainly as its metabolite N-acetyl-5-aminosalicylic acidNephrotoxicity has been reported Mesalazine is best avoided in patients with established renal impairment, but if necessary should be used with caution, and the patient carefully monitored
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt